In June 2000, Novartis restructured its pharmaceutical business division to develop international business entities in oncology, transplantation, ophthalmology, and mature goods. The other enduring primary care items were overlooked and supervised under international operations (e.g. R&D and marketing). The rejuvenated company initiated a matrix construct and restructured duties and job descriptions for heads of different business divisions, CEOs of new business sections, and country managers functional in more than 100 countries.
Form of Business Units Created at Novartis Pharmaceuticals
Creation of Marketing Focus
Quick Response to Changes in Market Dynamics
Inculcation of Entrepreneurial Spirit and Motivation of Staff
Creation of Reporting Conflicts
Less Focus on Long-Term Research and Development